查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2067468

恩氯米芬市場規模、佔有率和趨勢分析報告：按產品類型、劑量強度、適應症、分銷管道、地區和細分市場預測（2026-2033 年）

Enclomiphene Market Size, Share & Trends Analysis Report By Product Type, By Dosage Strength (Medium Dose ), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

恩氯米芬市場概覽

全球恩克洛米芬市場預計在 2025 年達到 2.16 億美元，預計到 2033 年將達到 4.1905 億美元，2026 年至 2033 年的複合年成長率為 8.70%。

這一成長是由男性性腺功能低下症的日益普遍，以及對增強內源性睾酮並保持生育能力的治療方法需求不斷增加所推動的。

男性健康意識的提高、診斷率的提升以及生育治療和內分泌護理服務的普及，進一步推動了市場需求。此外，從傳統的睪固酮替代療法轉向選擇性雌激素受體調節（SERMs），以及持續的臨床研究、研發和生活方式因素（例如延遲生育和荷爾蒙失衡），都在加速市場成長。然而，監管限制以及來自現有治療方法（例如枸櫞酸氯米芬）的競爭可能會減緩其普及速度。

恩氯米芬片段作為一種中等劑量（12.5-25毫克）的非類固醇類抗發炎藥，因其能在刺激體內睪固酮生成的同時維持生育能力，正日益受到臨床實踐和患者的關注。對於希望避免傳統睾酮替代療法（TRT）抑製作用的性腺功能減退男性患者而言，恩氯米芬片段正逐漸成為一種替代療法。恩氯米芬的作用機轉是阻斷下視丘中的雌激素受體，增加黃體激素（LH）和濾泡刺激素（FSH）的含量。這可以提高內源性睪固酮水平，而不會干擾下視丘-腦下垂體-性腺軸的功能。近期臨床數據，包括系統綜述/Meta分析，證實了選擇性雌激素受體調節（SERMs），例如恩氯米芬，能夠顯著改善功能性性腺功能減退男性患者的睪固酮、LH和FSH水平。與安慰劑相比，這些藥物具有潛在的優勢，可提供與局部應用睪固酮相當的荷爾蒙效果，同時還具有維持生育能力的額外益處。

此領域的成長主要受以下因素驅動：男性性腺功能低下症盛行率的上升、對能夠保留生育能力的睾酮療法的需求不斷成長，以及患者傾向於選擇中劑量（12.5-25毫克）治療方法，以避免注射和傳統睾酮替代療法（TRT）帶來的全身抑制。肥胖和第2型糖尿病等代謝和生活方式因素會導致次發性性性腺功能減退，進一步推動了人們對恩氯米芬等針對潛在荷爾蒙軸功能障礙的替代療法的興趣。臨床研究和Meta分析表明，與恩氯米芬類似的選擇性雌激素受體調節（SERM）不僅能有效提高睪固酮水平，而且比傳統睪固酮療法更能維持精子生成。這些優勢使其成為尋求療效和保留生育能力的男性的首選。醫護人員和病人對長期安全性和生活品質（QOL）改善的認知不斷提高，也進一步促進了其應用。隨著臨床應用案例和研究的不斷積累，該領域持續擴張，並更加重視以患者為中心的荷爾蒙管理。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：恩氯米芬市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：恩克洛米芬市場：依產品類型分類的商業分析

  • 按產品類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按產品類型分類，2021-2033 年
  • 枸櫞酸恩氯米芬片
  • 恩克洛米芬膠囊
  • 其他

第5章：恩氯米芬市場：按劑量強度分類的業務分析

  • 按劑量強度分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按劑量強度分類，2021-2033 年
  • 低劑量（12.5毫克或更少）
  • 中等劑量（12.5-25毫克）
  • 高劑量（25毫克以上）

第6章：恩氯米芬市場：依適應症分類的業務分析

  • 按適應症分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按適應症分類，2021-2033 年
  • 男性性腺功能低下症
  • 續發性功能減退症
  • 男性不孕
  • 其他

第7章：恩氯米芬市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章：恩克洛米芬市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Repros Therapeutics Inc.
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma Ltd.
    • Zydus Lifesciences Ltd.
    • Lupin Limited
    • Hetero Labs Limited
    • Sandoz International GmbH
    • Fresenius Kabi AG
Product Code: GVR-4-68040-905-5

Enclomiphene Market Summary

The global enclomiphene market size was estimated at USD 216.00 million in 2025 and is projected to reach USD 419.05 million by 2033, growing at a CAGR of 8.70% from 2026 to 2033. The growth is driven by the increasing prevalence of male hypogonadism and infertility, along with a growing preference for therapies that boost endogenous testosterone while preserving fertility.

Rising awareness of men's health, improved diagnosis rates, and expanding access to fertility and endocrinology care are further supporting demand. In addition, the shift toward selective estrogen receptor modulators over traditional testosterone replacement therapy, coupled with ongoing clinical research, product development, and lifestyle factors such as delayed parenthood and hormonal imbalances, is accelerating market growth, although regulatory constraints and competition from established treatments like clomiphene citrate may moderate adoption.

The enclomiphene segment has seen increasing clinical and patient interest as a non steroidal medium dose (12.5 mg - 25 mg) therapy that stimulates the body's own testosterone production while preserving fertility, positioning it as an alternative for men with hypogonadism who wish to avoid the suppressive effects of traditional testosterone replacement therapy (TRT). Enclomiphene works by blocking estrogen receptors in the hypothalamus and boosting luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which, in turn, elevate endogenous testosterone levels without shutting down the hypothalamic-pituitary-gonadal axis. Recent clinical data, including a 2025 - 2026 systematic review/meta-analysis of randomized controlled trials, confirmed that selective estrogen receptor modulators like enclomiphene significantly improve testosterone, LH, and FSH levels in men with functional hypogonadism, offering potential benefits over placebo and comparable hormonal effects to topical testosterone, with the added advantage of fertility preservation.

The segment's growth is driven by a rising prevalence of male hypogonadism, increasing demand for fertility sparing testosterone therapies, and patient preference for medium dose (12.5 mg - 25 mg) treatments that avoid injections and the systemic suppression associated with traditional TRT. Metabolic and lifestyle factors such as obesity and type 2 diabetes, which contribute to secondary hypogonadism, are further fueling interest in alternatives like enclomiphene that target underlying hormonal axis dysfunction. Clinical studies and meta-analyses have demonstrated that enclomiphene and similar selective estrogen receptor modulators (SERMs) not only effectively raise testosterone levels but also preserve spermatogenesis better than conventional testosterone therapies. These advantages make it a preferred option for men seeking both efficacy and fertility preservation. Growing awareness among healthcare providers and patients regarding long-term safety and quality-of-life benefits is further supporting adoption. As more real-world use and incremental research emerge, the segment continues to expand, emphasizing patient-centered hormonal management.

Global Enclomiphene Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global enclomiphene market report based on product type, dosage strength, indication, distribution channel, and region:

  • Product Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Enclomiphene Citrate Tablets
  • Enclomiphene Capsules
  • Others
  • Dosage Strength Outlook (Revenue, USD Million, 2021 - 2033)
  • Low Dose (<=12.5 mg)
  • Medium Dose (12.5 mg - 25 mg)
  • High Dose (>25 mg)
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Male Hypogonadism
  • Secondary Hypogonadism
  • Male Infertility
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Dosage Strength
    • 1.2.3. Indication
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Dosage Strength & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Enclomiphene Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Enclomiphene Market: Product Type Business Analysis

  • 4.1. Product Type Market Share, 2025 & 2033
  • 4.2. Product Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
  • 4.4. Enclomiphene Citrate Tablets
    • 4.4.1. Enclomiphene Citrate Tablets Market, 2021 - 2033 (USD Million)
  • 4.5. Enclomiphene Capsules
    • 4.5.1. Enclomiphene Capsules Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Enclomiphene Market: Dosage Strength Business Analysis

  • 5.1. Dosage Strength Market Share, 2025 & 2033
  • 5.2. Dosage Strength Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Dosage Strength, 2021 to 2033 (USD Million)
  • 5.4. Low Dose (<=12.5 mg)
    • 5.4.1. Low Dose (<=12.5 mg) Market, 2021 - 2033 (USD Million)
  • 5.5. Medium Dose (12.5 mg - 25 mg)
    • 5.5.1. Medium Dose (12.5 mg - 25 mg) Market, 2021 - 2033 (USD Million)
  • 5.6. High Dose (>25 mg)
    • 5.6.1. High Dose (>25 mg) Market, 2021 - 2033 (USD Million)

Chapter 6. Enclomiphene Market: Indication Business Analysis

  • 6.1. Indication Market Share, 2025 & 2033
  • 6.2. Indication Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 6.4. Male Hypogonadism
    • 6.4.1. Male Hypogonadism Market, 2021 - 2033 (USD Million)
  • 6.5. Secondary Hypogonadism
    • 6.5.1. Secondary Hypogonadism Market, 2021 - 2033 (USD Million)
  • 6.6. Male Infertility
    • 6.6.1. Male Infertility Market, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Enclomiphene Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. Enclomiphene Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Enclomiphene Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Enclomiphene Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Repros Therapeutics Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Type Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Viatris Inc.
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Type Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Teva Pharmaceutical Industries Ltd.
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Type Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sun Pharmaceutical Industries Ltd.
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Type Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Aurobindo Pharma Ltd.
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Type Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Zydus Lifesciences Ltd.
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Type Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Lupin Limited
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Type Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Hetero Labs Limited
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Type Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Sandoz International GmbH
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Type Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Fresenius Kabi AG
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Type Benchmarking
      • 9.5.10.4. Strategic Initiative

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Enclomiphene market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 5 Global Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 6 Global Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 7 Global Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 8 North America Enclomiphene market, by country, 2021 - 2033 (USD Million)
  • Table 9 North America Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 10 North America Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 11 North America Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 12 North America Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 U.S Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 14 U.S Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 15 U.S Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 16 U.S Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Canada Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 18 Canada Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 19 Canada Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 20 Canada Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 21 Mexico Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 22 Mexico Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 23 Mexico Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 24 Mexico Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 25 Europe Enclomiphene market, by country, 2021 - 2033 (USD Million)
  • Table 26 Europe Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 27 Europe Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 28 Europe Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Europe Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 UK Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 31 UK Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 32 UK Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 33 UK Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Germany Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 35 Germany Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 36 Germany Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 37 Germany Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 38 France Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 39 France Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 40 France Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 41 France Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Italy Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 43 Italy Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 44 Italy Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 45 Italy Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 46 Spain Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 47 Spain Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 48 Spain Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 49 Spain Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 50 Norway Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 51 Norway Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 52 Norway Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 53 Norway Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Denmark Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 55 Denmark Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 56 Denmark Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 57 Denmark Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 Sweden Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 59 Sweden Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 60 Sweden Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 61 Sweden Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific Enclomiphene market, by country, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 66 Asia Pacific Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Japan Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 68 Japan Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 69 Japan Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 70 Japan Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 71 China Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 72 China Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 73 China Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 74 China Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 75 India Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 76 India Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 77 India Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 78 India Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 79 Australia Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 80 Australia Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 81 Australia Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 82 Australia Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 83 South Korea Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 84 South Korea Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 85 South Korea Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 86 South Korea Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Thailand Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 88 Thailand Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 89 Thailand Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 90 Thailand Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 91 Latin America Enclomiphene market, by country, 2021 - 2033 (USD Million)
  • Table 92 Latin America Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 93 Latin America Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 94 Latin America Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 95 Latin America Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 96 Brazil Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 97 Brazil Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 98 Brazil Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 99 Brazil Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 100 Argentina Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 101 Argentina Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 102 Argentina Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 103 Argentina Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 104 Middle East & Africa Enclomiphene market, by country, 2021 - 2033 (USD Million)
  • Table 105 Middle East & Africa Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 106 Middle East & Africa Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 107 Middle East & Africa Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 108 Middle East Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 109 South Africa Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 110 South Africa Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 111 South Africa Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 112 South Africa Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 116 Saudi Arabia Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 117 UAE Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 118 UAE Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 119 UAE Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 120 UAE Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Enclomiphene market, by product type, 2021 - 2033 (USD Million)
  • Table 122 Kuwait Enclomiphene market, by dosage strength, 2021 - 2033 (USD Million)
  • Table 123 Kuwait Enclomiphene market, by indication, 2021 - 2033 (USD Million)
  • Table 124 Kuwait Enclomiphene market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Enclomiphene market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market dosage strength & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Enclomiphene market dynamics
  • Fig. 11 Enclomiphene market: Porter's five forces analysis
  • Fig. 12 Enclomiphene market: PESTLE analysis
  • Fig. 13 Product type market, 2021 - 2033 (USD Million)
  • Fig. 14 Enclomiphene citrate tablets market, 2021 - 2033 (USD Million)
  • Fig. 15 Enclomiphene capsules market, 2021 - 2033 (USD Million)
  • Fig. 16 Others market, 2021 - 2033 (USD Million)
  • Fig. 17 Dosage strength market, 2021 - 2033 (USD Million)
  • Fig. 18 Low dose (<=12.5 mg) market, 2021 - 2033 (USD Million)
  • Fig. 19 Medium dose (12.5 mg - 25 mg) market, 2021 - 2033 (USD Million)
  • Fig. 20 High dose (>25 mg) market, 2021 - 2033 (USD Million)
  • Fig. 21 Indication market, 2021 - 2033 (USD Million)
  • Fig. 22 Male hypogonadism market, 2021 - 2033 (USD Million)
  • Fig. 23 Secondary hypogonadism market, 2021 - 2033 (USD Million)
  • Fig. 24 Male infertility market, 2021 - 2033 (USD Million)
  • Fig. 25 Others market, 2021 - 2033 (USD Million)
  • Fig. 26 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 27 Hospital pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 28 Retail pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 29 Online pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 30 Enclomiphene market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 39 Europe Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 44 France country dynamics
  • Fig. 45 France Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark country dynamics
  • Fig. 55 Denmark Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 56 Asia Pacific Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 59 China country dynamics
  • Fig. 60 China Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 61 India country dynamics
  • Fig. 62 India Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 69 Latin America Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 74 MEA Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait Enclomiphene market, 2021 - 2033 (USD Million)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework